Cyclopharm defers US guidance despite $17.1M revenue

• Cyclopharm has deferred its short-term US installation guidance due to the delayed publication of international clinical guidelines.
• The company reported record preliminary global revenue of approximately $17.1 million for the first half of FY26.
• The finalised clinical guidelines have broadened to cover the US, European, and regional markets to drive long-term growth.

Cyclopharm (ASX:CYC) deferred its short-term US installation guidance due to delayed clinical guidelines, despite reporting record global revenue of approximately $17.1 million.

This delay contrasts with the group's ongoing commercial acceleration, which delivered an 11% revenue increase over last year.

The company stated that it now expects to reach 250–300 total revenue-generating US locations after Dec. 31.

The company also reaffirmed its confidence in achieving its medium-term target of over 2000 installations in the United States.

While the company awaits the official publication to expand its rollout following the announcement, the Cyclopharm share price was up at $0.53.

The broader commercial strategy relies on the expanded guidelines, which now cover the US, European, and regional markets.

This milestone follows a multi-stage review process by international medical societies.